Parnax Lab

Parnax Lab Stock-Based Compensation

Stock-Based Compensation (SBC) of Parnax Lab (506128.BO) as of Oct 16, 2026.

Stock-Based Compensation

-INR

Last updated:

Stock-Based Compensation (SBC) of Parnax Lab is 2026 - INR. Stock-Based Compensation (SBC) of Parnax Lab was 2025 - INR. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Parnax Lab Stock analysis

What does Parnax Lab do? Parnax Lab Ltd, listed on the Bombay Stock Exchange with ticker 506128.BO and ISIN INE383L01019, is headquartered in Mumbai, India. The company operates in the Health Care sector within the Pharmaceuticals industry. It employs 12 full-time staff and completed its IPO on September 15, 2009. Parnax Lab Ltd manufactures and trades pharmaceutical formulations, including oral products such as cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric formulations, viscous products, and suspensions. The company also has a subsidiary, Naxpar Pharma Private Limited. Parnax Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Parnax Lab stock

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Parnax Lab since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Parnax Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Parnax Lab

All Key Metrics — Parnax Lab